GAMUT THERAPEUTICS
GAMUT Therapeutics is a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (“RP”).
GAMUT THERAPEUTICS
Industry:
Biotechnology Therapeutics
Address:
Paris, Ile-de-France, France
Country:
France
Status:
Active
Similar Organizations
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
More informations about "GAMUT Therapeutics"
SparingVision Expands Novel Ocular Disease Pipeline with …
Apr 20, 2021 Dr. Deniz Dalkara, scientific founder of GAMUT Therapeutics, said: “GAMUT was founded to progress cutting-edge science into application as a gene therapy product for …See details»
GAMUT Therapeutics - Crunchbase Company Profile & Funding
Organization. GAMUT Therapeutics . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. GAMUT is a biotechnology company pioneering a unique …See details»
SparingVision Expands Novel Ocular Disease Pipeline with
Apr 20, 2021 In acquiring GAMUT Therapeutics, we have added a second gene-independent approach to our product pipeline for rod-cone dystrophies, which has the potential to be …See details»
Gamut Therapeutics - Drug pipelines, Patents, Clinical trials
May 8, 2025 In April 2021, SparingVision acquired the biotech GAMUT Therapeutics, which also gave it access to the company’s lead candidate, which was renamed SPVN20. The Phase I …See details»
SparingVision sells ex vivo GIRK technology to Tenpoint …
Jul 12, 2023 SparingVision’s core focus is on in vivo technologies and since the acquisition of GAMUT it has looked to capitalize on the potential of its ex-vivo GIRK technology. Together …See details»
GAMUT Therapeutics acquired by SparingVision - Crunchbase
Apr 20, 2021 GAMUT Therapeutics GAMUT is a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies. Acquiring …See details»
Three questions for Geoffroy de Ribains, operating partner at AFB …
Apr 20, 2021 and other key partners such as the French tech transfer organization SATT Lutech. GAMUT Therapeutics was born: a biotechnology company pioneering a unique gene …See details»
SparingVision enters agreement to acquire Gamut …
Apr 21, 2021 Geoffroy de Ribains, Operating Partner at Advent France Biotechnology and CEO of Gamut Therapeutics, commented: “We are really pleased with this acquisition – it provides a unique opportunity to speed up the …See details»
RSM conducted the financial due diligence for SparingVision …
Apr 26, 2021 SparingVision: Acquisition of GAMUT Therapeutics SparingVision, a genomic medicine company developing treatments for eye diseases, announced on Tuesday, April 20, …See details»
SparingVision acquires GAMUT Therapeutics – Ysios Capital
Apr 20, 2021 Dr. Deniz Dalkara, scientific founder of GAMUT Therapeutics, said “GAMUT was founded to progress cutting-edge science into application as a gene therapy product for …See details»
Gamut Therapeutics - PitchBook
Gamut Therapeutics was founded in 2020. Where is Gamut Therapeutics headquartered? Gamut Therapeutics is headquartered in Paris, France. What industry is Gamut Therapeutics in? Gamut Therapeutics’s primary industry is …See details»
SparingVision expands ocular disease pipeline with buy of GAMUT ...
Apr 20, 2021 Ocular diseases focussed genomics medicines company SparingVision has entered into a definitive agreement to acquire fellow French biotech firm GAMUT …See details»
SparingVision Expands Novel Ocular Disease Pipeline with …
Paris, April 20, 2021 – SparingVision (the “Company”), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive …See details»
SparingVision to Acquire Therapy for Resurrecting Dormant Cones …
Apr 26, 2021 SparingVision, a genomic medicines company targeting ocular diseases, has entered into an agreement to acquire GAMUT Therapeutics, a company developing a gene …See details»
GAMUT Therapeutics - Crunchbase
GAMUT is a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies. New. ... Experience the new Crunchbase, powered by AI …See details»
SparingVision Has Entered Into a Definitive Agreement to Acquire …
Apr 22, 2021 The Paris Private Equity team advises SparingVision as it has entered into a definitive agreement for the acquisition of GAMUT Therapeutics, a biotechnology company …See details»
GAMUT Therapeutics - Products, Competitors, Financials, …
GAMUT's lead product, SPVN20, is a novel, mutation-agnostic gene therapy, which aims at restoring the function of dormant cone cells in the retina. Dormant cones are viable cones that …See details»
GAMUT THERAPEUTICS - Societe.com
Jul 1, 2020 505989 Petites-Affiches GAMUT THERAPEUTICS Société par actions simplifiee au capital de 1.200 EUR Siège social : 4 Rue Thénard 75005 PARIS 884 795 741 R.C.S. Paris …See details»
SparingVision Expands Novel Ocular Disease Pipeline with …
Apr 20, 2021 SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Paris, April 20, 2021 – SparingVision (the “Company”), a genomic medicines …See details»
Advent France Biotechnology crée Gamut Therapeutics et finance …
Paris, France, le 15 décembre 2020 – Advent France Biotechnology (AFB), société de capital-risque spécialisée dans l’amorçage en sciences de la vie, annonce aujourd’hui la création de …See details»